Organization
UCLA Department of Nuclear Medicine, Los Angeles, CA
4 abstracts
Abstract
Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.Org: Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, University of California, San Francisco, San Francisco, CA, Department of radiology and biomedical imaging, University of California, San Francisco, San Francisco, CA, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany, Department of Nuclear Medicine, University of California, Los Angeles, CA,
Abstract
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.Org: UCLA Ahmanson Translational Theranostics Division, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UCLA Nuclear Medicine, Department of Radiology and Biomedical Imaging, University of California Irvine,
Abstract
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.Org: University of Duisburg-Essen and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, Peter MacCallum Cancer Centre, Melbourne, Australia, UCLA Department of Nuclear Medicine, Los Angeles, CA, University of California Los Angeles, Los Angeles, CA,
Abstract
Head-to-head comparison of 68Ga-PSMA-11 PET with 99mTc-MDP bone scan for detection of bone disease in patients with prostate cancer with biochemical progression during ADT: A single center prospective study.Org: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, University of California Irvine, University of California Los Angeles, UCLA Department of Medical Oncology, UCLA Department of Nuclear Medicine, Los Angeles, CA,